Trastuzumab biosimilar - Alteogen/Cristalia/Qilu Pharmaceutical

Drug Profile

Trastuzumab biosimilar - Alteogen/Cristalia/Qilu Pharmaceutical

Alternative Names: ALT 02; ALT L2

Latest Information Update: 11 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alteogen
  • Developer Alteogen; Cristalia; Qilu Pharmaceutical
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer; Gastric cancer

Most Recent Events

  • 26 Apr 2017 Phase-I clinical trials in Breast cancer in Canada (SC)
  • 26 Apr 2017 Phase-I clinical trials in Gastric cancer in Canada (SC)
  • 20 Apr 2017 Alteogen plans phase III trials and intends to seek marketing approval post their completion
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top